Cincinnati, OH-Oct. 27, 2009
Schulman Associates IRB (Schulman) has expanded its IRB services into Canada with an office in Toronto because of requests from clients, according to the company. The Schulman Canadian Board’s first official meeting is scheduled for this week.
For North American studies which are conducted in both the U.S. and Canada, Canadian and U.S. Board members will review the research together in order to maintain consistency.
“Our clients have asked us to provide review services in Canada. Now that our Canadian IRB is operational, Schulman can provide the same...review for Canadian research as it has provided in the U.S. for the past 26 years,” said Schulman’s CEO, John Isidor.
Schulman provides clients conducting Canadian studies with access to its WebPortal 2.0 service. WebPortal 2.0 interfaces directly with Schulman’s internal system to provide Sponsors and CROs with real-time updates on review status and timelines.
Early next year, Schulman will launch updated electronic tools to provide clients with greater access to critical review information. Schulman’s existing submission forms have been revised to comply with Canadian regulations and terminology. The revisions are minor and the forms will remain familiar to Schulman clients who have used them for U.S. studies.
French-speaking support is available for Canadian studies. Schulman’s U.S. institutional review board is fully accredited by the Association for Accreditation of Human Research Protection Programs (AAHRPP).
For more information on Schulman call Client Services at 513-761-4100 or visit www.sairb.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes
June 24th 2025In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained weight loss of up to 20% in adults with obesity, with or without type 2 diabetes, alongside notable improvements in glycemic control, supporting its advancement to Phase III studies as a potential once-monthly treatment option.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.